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HBcAgA plasmid carrying 1.3-fold HBV genome was constructed from a HBV strain that caused ﬁve consecutive
cases of fulminant hepatitis (pBFH2), and HepG2 cells were transfected with pBFH2 or its variants. The
pBFH2 construct with A1762T/G1764A, G1862T, and G1896A showed the largest amount of core particle-
associated intracellular HBV DNA, but no signiﬁcant increase of extracellular HBV DNA in comparison with
the wild construct, suggesting that these mutations might work together for retention of the replicative
intermediates in the cells. The retention might relate to the localization of hepatitis B core antigen (HBcAg)
in the nucleus of HepG2, which was observed by confocal ﬂuorescence microscopy. HBcAg immunohisto-
chemical examination of liver tissue samples obtained from the consecutive fulminant hepatitis patients
showed stronger staining in the nucleus than acute hepatitis patients. In conclusion, the fulminant HBV
strain caused retention of the core particles and the core particle-associated HBV DNA in the cells.
© 2009 Elsevier Inc. All rights reserved.Introduction
Hepatitis B virus (HBV) causes a spectrum of liver diseases such as
acute self-limiting or fulminant hepatitis, chronic hepatitis, liver
cirrhosis, and hepatocellular carcinoma. Fulminant hepatitis, which is
lethal during a short period in many cases, occurs in approximately 1%
of patients with acute HBV infection (Lee, 1993). The pathogenesis
that leads to fulminant hepatitis B is considered to result from
enhanced replication of the virus (Baumert et al., 1996; Hasegawa et
al., 1994) and the exuberant immune response of the host (Rivero et
al., 2002), but it is not fully understood.
HBV contains a small (3.2 kb), circular, partially double-
stranded DNA genome. This genome includes four, partly over-
lapping open reading frames: the precore/core gene encoding for
the hepatitis B e antigen (HBeAg) and the core antigen (HBcAg),
the polymerase gene encoding for the polymerase protein, the
preS/S gene encoding for the hepatitis B surface antigen (HBsAg),
and the X gene encoding for the X protein. In the course of
replication, four kinds of viral RNAs, 3.5, 2.4, 2.1, and 0.8 kb in size,eno).
, Sendai City Hospital, Sendai
ll rights reserved.are transcribed (Ganem and Varmus, 1987). There are two types of
3.5 kb RNAs whose 5′ termini and functions are different: the
pregenomic RNA (pgRNA) and the precore mRNA. The pgRNA,
which is encapsidated as the template for reverse transcription to
generate viral DNA, serves as the mRNA for HBcAg and the
polymerase protein (Summers and Mason, 1982). The precore
mRNA is translated into the precore/core fusion protein that is
post-translationally modiﬁed to HBeAg (Roossinck et al., 1986;
Standring et al., 1988). The transcription of the pgRNA and the
precore mRNA are regulated by the core promoter corresponding
to nucleotide (nt) 1613–1849 (Kramvis and Kew, 1999). The
double core promoter mutations of A1762T/G1764A, which were
frequently observed in HBeAg-negative chronic hepatitis patients
(Okamoto et al., 1994) and fulminant hepatitis patients (Sato et al.,
1995), were reported to reduce the production of HBeAg and
enhance the replication of HBV in an in vitro study (Buckwold et
al., 1996; Moriyama et al., 1996). It was also documented that the
precore mutation of G1896A, which makes a stop codon and
abrogates HBeAg (Carman et al., 1989), was associated with
fulminant hepatitis (Liang et al., 1991; Omata et al., 1991), and
the enhanced replication of HBV with G1896A in vitro has been
described (Ozasa et al., 2006; Scaglioni et al., 1997).
Recently, we reported ﬁve consecutive cases of fulminant
hepatitis B that were caused by the same strain of HBV (Nagasaki
et al., 2008). The full-length sequences of HBV obtained from them
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genotype B2 (Ba), which was reported to cause fulminant hepatitis
less frequently than genotypes A, C, D, and other subgenotypes of
genotype B (Ozasa et al., 2006). The fulminant strain was found to
have several mutations in the core promoter and precore regions.
The aim of this study is to investigate the signiﬁcance of these
mutations in the pathogenesis of fulminant hepatitis, using an in
vitro culture system.
Results
Mutations in the fulminant strain of HBV
In the fulminant HBV strain FH-2, many mutations throughout
the genome were observed. The full-length sequence (accession
number: AB302943) (Nagasaki et al., 2008) was compared with a
genotype B2 consensus sequence that was deduced from 52 full-
length sequences deposited on GenBank/EMBL/DDBJ. A total of 45
nucleotide mutations, including the double core promoter muta-
tions of A1762T/G1764A and the precore stop mutation of G1896A,
were found. In the precore region, a distinctive mutation of
G1862T located within the bulge of the ɛ signal as an RNA
structure (Fig. 1C) was also found. Other nucleotide mutations
were not found in the core promoter and precore regions except
for G1632C. Because nt 1632 varies in the known genotype B2
strains, the nucleotide was considered not to have an important
role in the pathogenesis of fulminant hepatitis.
As for amino acid (aa), 17 mutations in the polymerase gene, 7
mutations in the preS/S gene, 6 mutations in the precore/core gene,
and 6 mutations in the X gene were observed (Table 1). Focusing on
the core promoter and precore regions, an amino acid mutation of
residue 17 of Val to Phe (V17F) in the precore region was found
besides the precore stop mutation and the double core promoter
mutations (corresponding to aa 130 and 131 in the X gene). V17F in
the precore region corresponds to the G1862T mutation. We
suspected that the nonsynonymous mutations of G1862T mightFig. 1. Construction of a plasmid (pBFH2) andmutations in the strain. (A) Schema of the plas
the core promoter and the precore region. (B) Nucleotide mutations and corresponding a
structure of the ɛ signal as an RNA secondary structure. It consists of two base-paired segmen
is within the lower stem. En, enhancer; preC/C, precore/core; P, polymerase.have some effects on the development of fulminant hepatitis,
besides A1762T/G1764A and G1896A.
Validation of the replication capacity and the transfection efﬁciency
A plasmid containing 1.3-fold genome of the FH-2 strain, named
pBFH2, was transfected to HepG2 or Huh7 cells, and the replication
capacity of the strain was compared in these cell lines. Because the
amount of HBsAg and HBV DNA in the culture medium was
signiﬁcantly larger in HepG2 than Huh7 (Fig. 2A), HepG2 was used
in the following experiments.
To investigate the signiﬁcance of the mutations of A1762T/
G1764A, G1862T, and G1896A in the FH-2 strain, pBFH2 and its
variants were transfected to HepG2 cells and compared. First, the
efﬁciency of transfection was validated using the SEAP reporter
system. It was shown that the differences in the activity of SEAP
between pBFH2 and its variants coincided with that of expressed
HBsAg (Fig. 2B). Therefore, the assay of HBsAg was thought to be
suitable for the validation of the transfection efﬁciency in this system.
Intracellular replicative intermediates of HBV
Southern blotting analysis was performed using HepG2 collected
3 days after transfection. Intracellular core particle-associated
HBV DNA was shown as replicative intermediates such as relaxed
circular DNA, double-stranded linear DNA, and single-stranded DNA
(Fig. 3A). The amount of intracellular HBV DNA was measured by
densitometry (Fig. 3B). When compared with the all-wild construct
(A1762/G1762, G1862, and G1896), the intracellular HBV DNA was
decreased signiﬁcantly in the construct with the single mutation
of G1862T. This ﬁnding was in agreement with a previous report
(Guarnieri et al., 2006). However, the suppression of HBV
replication was overcome by the coexisting mutation of A1762T/
G1764A or G1896A. Moreover, only the all-mutant original
construct, pBFH2, showed signiﬁcantly larger amounts of intracel-
lular HBV DNA than the all-wild construct. The double mutations ofmid containing 1.3-fold HBV genome and the positions of nucleotide mutations found in
mino acid mutations in the core promoter and the precore region in pBFH2. (C) The
ts (lower and upper stems), a bulge, and a loop. nt 1862 is within the bulge and nt 1896
Fig. 2. (A) Comparison of replicative capacity of the FH-2 strain in HepG2 and Huh7.
HBsAg and HBV DNA in the culture medium were assayed by ELISA and real-time PCR,
respectively. ⁎, Pb0.05. (B) Validation of transfection efﬁciency using the SEAP reporter
system. The SEAP activity in the culture supernatant was compared with HBsAg, and it
was evaluated to determine whether the HBsAg assay was appropriate for the
validation of transfection efﬁciency. Values represent means of triplicate experiments
±standard deviation.
Table 1
Differences of amino acids between the B2 consensus sequence and the FH-2 strain.
Gene aa position B2 consensusa FH-2
Polymerase 50 Ile Thr
93 Lys Glu
104 Asn Thr
118 Asn Lys
150 Thr Ile
212 Pro Ser
261 Gly Asp
266 His Asn
301 Ala Thr
464 Asn Asp
470 Asn His
474 Thr Asn
480 Asn Asp
566 Leu Ile
678 Ser Arg
679 Lys Asn
809 Thr Ser (Phe)b
preS/S 81 Ala Thr
120 Met Ile
132 Gln His
214 Asn Ser
250 Cys Tyr
294 Pro Thr
358 Val Ala
Precore/core 17 Val Phe
28 Trp Stop
106 Glu Gln
108 Pro Gln
113 Leu Ala
210 Ser Pro
X 37 Leu Val
44 Val Ala
48 Asp Ile
87 Gly Arg
130 Lys Met
131 Val Ile
a Deduced from 52 full-length sequences of genotype B2 HBV registered on
GenBank/EMBL/DDBJ.
b Found in the other isolates obtained from consecutive cases of fulminant hepatitis.
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G1896A, had a tendency to increase the replicative intermediates,
but not signiﬁcantly. The single G1896A mutation did not seem to
increase them.
Released HBV virions and HBeAg
The amount of the yielded HBV virions in the culture supernatant
of pBFH2-transfected HepG2 was assayed by real-time PCR and
comparedwith pBFH2-variant constructs (Fig. 4). The single mutation
of G1862T reduced it signiﬁcantly whereas the double mutation of
A1762T/G1764A increased it. Notably, the amount was not increased
signiﬁcantly for pBFH2, in contrast to the result of intracellular HBV
DNA. These data suggested that pBFH2 might cause accumulation of
the replicative intermediates in the cells due to the mutations in the
core promoter and precore region.
The secreted HBeAg was reduced in the pBFH2-variant constructs
with A1762T/G1764A and/or G1896A expectedly (Fig. 4), but the
effect of A1762T/G1764A was limited in this study. Consistent with a
previous report (Guarnieri et al., 2006), G1862T did not seem to affect
the expression of HBeAg.
Distribution of HBcAg in HepG2 cells
To investigate the mechanism of the retention of viral
replicative intermediates in the cells, the relationship between
the distribution of HBcAg in the cells and the mutations of HBV
was analyzed using confocal microscopy (Fig. 5). The all-wildconstruct showed weak HBcAg staining mainly in the nucleus. The
construct with only A1762T/G1764A showed the predominant
distribution of HBcAg in the cytoplasm, which was concordant with
a previous report (Kawai et al., 2003; Liu et al., 2009). The
predominant distribution of HBcAg in the nucleus was observed in
the construct with the single mutation of G1896A. Although the
construct with only G1862T showed HBcAg staining mainly in the
cytoplasm, strong staining of HBcAg was observed in the nucleus of
the transfected cells of the all-mutant construct, pBFH2. The
relationship between the predominance of the HBcAg distribution
and the amount of intracellular/extracellular HBV DNA is shown in
Table 2. The constructs demonstrating predominant HBcAg distri-
bution in the cytoplasm, such as the construct having only
A1762T/G1764A, had a tendency to yield a large amount of
extracellular HBV DNA in comparison with intracellular HBV DNA.
In contrast, pBFH2, which produced the largest amount of
intracellular HBV DNA, showed HBcAg distribution in the nucleus.
Whereas the HBcAg distribution in the cytoplasm might lead to the
efﬁcient release of the HBV particles, its distribution in the nucleus
might be related to the retention of replicative intermediates in the
cells. The same results were obtained also using a mouse
monoclonal anti-HBcAg antibody (Hyb-3120; Institute of Immu-
nology, Tokyo, Japan), which recognizes a capsid conformation-
speciﬁc epitope and not HBeAg (Conway et al., 2003) (data not
shown). Taken together, the presence of all of the mutations of
A1762T/G1764A, G1896A, and G1862T was considered to work
together to accumulate HBV DNA in the cells via retention of HBV
core particles in the nucleus.
Fig. 4. Released HBV particle and HBeAg in the culture supernatant. The amount of HBV
particle was measured by real-time PCR and HBeAg was assayed by ELISA. In the top,
the means of HBsAg in the culture supernatant are shown. Values represent means of
triplicate experiments±standard deviation. ⁎, Pb0.05 in comparison with the all-wild
construct.
Fig. 3.Detection of replicative intermediates of HBV by Southern blotting analysis. (A) A
result of a representative experiment of Southern blotting analysis. + indicates the
mutant nucleotides in each nucleotide and − indicates the wild-type nucleotides. RC,
relaxed circular HBV DNA; ds-L, double-stranded linear HBV DNA; ss, single-stranded
HBV DNA. (B) Amount of replicative intermediates measured by densitometry, in
comparison with the density of 150 pg HBVmarker. The bars indicate themean value of
triplicate experiments±standard deviation. Means of HBsAg assayed by ELISA were
shown as markers for transfection efﬁciency. ⁎, Pb0.05 in comparison with the all-wild
construct.
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To evaluate the results of in vitro study, immunohistochemical
examination of liver specimens was performed using the same
primary antibody to HBcAg (Fig. 6). In the samples obtained from
three of ﬁve consecutive fulminant hepatitis B patients, both the
nucleus and the cytoplasm of hepatocytes were stained (Figs. 6A–C).
In contrast, nuclear staining was rarely observed in acute hepatitis B
patients (Figs. 6D–F). In a chronic hepatitis B patient for positive
control, nuclear staining was observed (Fig. 6G). Although the
cytoplasmic HBcAg was observed more strongly in the tissue samples
of fulminant hepatitis than the pBFH2-transfected cells in vitro, it was
shown that HBcAg was retained in the nucleus of hepatocytes of these
fulminant hepatitis patients. It was considered that the ﬁndings from
the tissue samples supported the results from pBFH2-transfected
cells, in which the core particle-associated replicative intermediates
of HBV were retained.
Discussion
A large body of evidence has demonstrated that HBV-related liver
disease is immune-mediated (Chisari, 1997; Kondo et al., 1997;
Perrillo, 2001). Whereas strong and multispeciﬁc T cell responses are
observed during acute HBV infection, patients with chronic hepatitis Btend to have weak and narrowly focused immune responses (Chisari,
1997). However, immunocompromised hosts such as patients
undergoing hemodialysis can develop fulminant hepatitis B (Igaki et
al., 2003), indicating that both viral factors as well as the host immune
response are involved in the pathogenesis of fulminant hepatitis. In
our study, all of the ﬁve consecutive patients with fulminant hepatitis
B were over 60 years old and might have had relatively weaker
immune responses to HBV. Therefore, the HBV strain obtained from
them is considered to be appropriate for the study of the viral factors
that lead to fulminant hepatitis.
The fulminant strain of genotype B2 in this study had several
mutations including A1762T/G1764A and G1896A, and additionally,
G1862T was found in the precore region. It was reported that G1862T
was found frequently in the HBV of fulminant hepatitis patients
without A1762T/G1764A and G1896A in China, where genotype B2
HBV is prevalent (Hou et al., 2002). In that report, G1862T caused a
reduction of HBeAg, which might be associated with the development
of fulminant hepatitis. However, another report using a genotype D
strain described that the mutation did not change the expression of
HBeAg but reduced the expression of the core protein and impaired
HBV replication (Guarnieri et al., 2006). These reports are controver-
sial and further analysis of this mutation is needed.
This study demonstrated that the precore G1862T mutation
caused the accumulation of the core particle-associated HBV DNA in
the cells, in conjunction with the core promoter A1762T/G1764A and
precore G1896Amutations. nt 1862 could have two possible functions
in the replication of HBV based on the position in the precore
Fig. 5. Comparison of the distribution of HBcAg in the transfected HepG2 cells observed by confocal microscopy according to the HBV mutations. HBcAg was stained using a rabbit
polyclonal anti-HBcAg antibody (Dako), and F-actin and nucleus were stained simultaneously.
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Table 2
The summarized results of the intracellular/extracellular HBV DNA and distribution of
HBcAg in the nucleus according to HBV mutations.
HBV mutations Intracellular Extracellular HBcAg
distributionb
A1762T/G1764A G1862T G1896A HBV DNAa HBV DNAa
− − − + + NNC
+ − − + ++ CNN
− + − ± ± CNN
− − + + + NNC
+ + − + + CNN
+ − + + ++ CNN
− + + + ± NNC
+ + + ++ + NNC
a ++ indicates that the amount of HBV DNA was signiﬁcantly larger than the all-
wild (A1762/G1764, G1862, and G1896) construct, and ± indicates that the amount
was signiﬁcantly lower than the all-wild construct. + indicates no signiﬁcant change
relative to the all-wild construct.
b NNC indicates that the cells having HBcAg in the nucleus were observed more
predominantly than those having HBcAg in the cytoplasm, and CNN indicates the
opposite frequency.
Fig. 6. HBcAg immunohistochemical examination of the liver tissue samples obtained
from fulminant hepatitis B (FH-B) patients and acute hepatitis B (AH-B) patients using a
rabbit polyclonal anti-HBcAg antibody (Dako). (A–C) Tissue samples of three of ﬁve
consecutive fulminant hepatitis B patients fromwhom the FH-2 strain was isolated. The
arrows indicate the hepatocytes with nuclear HBcAg staining. (D–F) Tissue samples
obtained from three acute hepatitis B patients. (G) A sample obtained from a chronic
hepatitis B (CH-B) patient as positive control. (H) A sample of a nonalcoholic
steatohepatitis (NASH) patient as negative control.
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the precore peptide and can affect processing of the precore/core
protein into HBeAg (Chen et al., 2008; Hou et al., 2002) and (ii) it is
within the bulge of the ɛ signal, which works as the template for the
primers to synthesize the negative-strand DNA (Nassal and Rieger,
1996), and is recognized by HBV polymerase in the encapsidation of
the pgRNA into the core particle (Rieger and Nassal, 1995). As for the
former, aa 17 in the precore peptide is located at the −3 position of
the signal peptidase cleavage site, and phenylalanine in this position is
considered a “forbidden” amino acid, which may abrogate the
cleavage of the precore/core protein by the signal peptidase. Although
the effect of G1862T on the production of HBeAg is controversial
(Chen et al., 2008; Guarnieri et al., 2006; Hou et al., 2002), it could be
supposed that the single mutation of G1862T has a suppressive effect
on HBV replication, at least in in vitro studies using genotype D strains
(Chen et al., 2008; Guarnieri et al., 2006). A protein of 22 kDa (p22)
including precore peptide, which is a product from the precore/core
protein other than HBeAg, was reported to inhibit encapsidation
(Kimura et al., 2005; Scaglioni et al., 1997). Hence, it was suspected
that the possibly increased p22, which might not be cleaved due to
G1862T, might lower the capacity of HBV encapsidation and
replication. The ﬁnding in this study that the replication capacity
was overcome by the precore stopmutation G1896A, which abrogates
the precore/core protein, supports this speculation. In view of the
function of the bulge of the ɛ signal, G1862T could make the extended
templates for the initiation of the negative-strand DNA replication.
Whereas the primer of TGAA is made using the 3′-part of the bulge
as the template in wild-type HBV, the extended primer of TGAAA
or TGAAAA which can anneal to the direct repeat 1 (DR1) and the
continued 5′ nucleotides (5′-CTTTTTCACCTCTGCCT-3′, italic-typed
nucleotides are the DR1 sequence and underlined nucleotides are
complement to the extended primer) can be made in the presence of
G1862T. Although it is unknown whether the extended primer can
actually initiate the extension of the negative-strand DNA, the primer
may have some positive effects on reverse transcription. Some of the
possible effects of G1862T on the viral replication can be affected by
other mutations and the phenotype may be changed.
The core promoter mutation of A1762T/G1764A, which is known
to enhance the transcription of pgRNA and reduce the precore mRNA
(Moriyama et al., 1996), was described as being associated with the
cytoplasmic distribution of HBcAg (Kawai et al., 2003; Liu et al., 2009).
In this study, the localization of HBcAg was changed to the nucleus
when both G1862T and G1896A were present. Whereas HBcAg is a 21
kD protein (p21) and can be transported across the nuclear
membrane by diffusion, the core particle, which consists of approx-
imately 180 subunits of a core protein, cannot diffuse across it (Forbes,1992; Kawai et al., 2003). It has been speculated that high density
HBcAg resulting from the increased pgRNA in the presence of
A1762T/G1764A might favor the formation of the core particle in
the cytoplasm, and the release of the particle as an infectious virus
particle after envelopment. A part of the incompletely processed
precore/core protein, p22, can also assemble into the core particle, but
the particle cannot encapsidate the pgRNA (Scaglioni et al., 1997). The
empty core particle could be detected also in this study using the
polyclonal anti-HBcAg antibody. As G1862T reduces HBcAg expres-
sion (Guarnieri et al., 2006) and G1896A abrogates the precore/core
protein, the presence of these mutationsmay lower the density of p21
and p22 leading to inefﬁcient assembly of the core particle in the
cytoplasm. After that, unassembled p21 is transported across the
nuclear membrane by the function of the putative nucleolar
localization signal of HBcAg (Ning and Shih, 2004) and be assembled
in the nucleus, followed by formation of the core particle. As the
particles cannot be transported across the nuclear membrane, they
may accumulate in the nucleus.
The core promoter mutations of A1762T/G1764A change over-
lapping X protein, and there is a possibility that the change of X
protein may have effect on HBV replication or localization. A recent
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do not affect expression of the X gene or impair its stimulatory effect
on viral genome replication (Hussain et al., 2009). The effect of the
mutant X protein on the viral localization remains unclear and has to
be elucidated in the future study.
We also performed HBcAg immunohistochemical examination of
the liver tissue samples, and it was conﬁrmed that HBcAg was
retained in the hepatocytes of fulminant hepatitis patients, from
whom the fulminant HBV strain was isolated. In these samples,
HBcAg was observed in the cytoplasm besides the nucleus. The
different distribution pattern of HBcAg between in vitro and in vivo
might be due to many differences of conditions such as the
characteristics of cells and the absence/presence of immune system.
Generally, it is thought that HBV-infected hepatocytes are targeted
by immune system including T cells (Chisari, 1997), and that the
immune response is strongly induced in fulminant hepatitis
patients. The retained HBcAg in the cells could induce such immune
response. Alternatively, it is speculated that the retained viral
proteins might have direct cytopathic effects. Ning and Shih (2004)
reported that cells showing the nucleolar localization of HBcAg
were often apoptotic, suggesting that the presence of HBcAg in the
nucleus may perturb cytokinesis. It was also suggested that the
large surface protein or X protein of HBV induced apoptosis (Chirillo
et al., 1997; Foo et al., 2002). A strain of HBV that was associated
with a fatal outbreak of fulminant hepatitis showed enhanced
replication and induced apoptosis in primary Tupaia hepatocytes
(Baumert et al., 2005). Interestingly, Sugiyama et al. (2006) showed
that the endoplasmic reticulum stress, which was evaluated by the
Grp78 promoter activity in genotype A to D HBVs obtained from
HBeAg positive patients, was the highest in genotype B2. If the
endoplasmic reticulum stress is enhanced further by the retained
intracellular viral proteins including HBcAg, apoptosis or inﬂamma-
tion might be promoted, resulting in fulminant hepatitis. Further
studies are needed to clarify whether such retention is caused by
other fulminant HBV strains.
In conclusion, the fulminant HBV strain that was isolated from
consecutive fulminant hepatitis patients retained the core particles
and the core particle-associated HBV DNA in the cells. The mutations
of A1762T/G1764A, G1862T, and G1896Amight work together for the
retention. These ﬁndings may have important implications for
understanding the mechanism leading to fulminant hepatitis.
Materials and methods
Construction of plasmids
Using serum of one of the consecutive patients with fulminant
hepatitis B (FH-2) in Japan (Nagasaki et al., 2008), total DNA was
extracted with QIAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden,
Germany) and subjected to nested polymerase chain reaction (PCR)
for two overlapping fragments; the ampliﬁed fragments were nt
1051–3215/1–327 (2492 nt; fragment A) and nt 180–1953 (1774 nt;
fragment B). PCR was performed with high ﬁdelity polymerase,
PrimeSTAR HS DNA polymerase (TaKaRa Bio, Inc., Shiga, Japan). The
ampliﬁcation products were cloned into pUC118 vectors, and digested
with XbaI. The fragments A and B were ligated, and ﬁnally, a plasmid
containing 1.3-fold HBV genome (nt 1051–3215/1–1953) was
constructed and named pBFH2 (Fig. 1A).
QuikChange II-E Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA) was used to introduce nucleotide substitutions into pBFH2.
Each mutation found in the core promoter and precore regions,
A1762T/G1764A, G1862T, and G1896A (Fig. 1B), was converted into
wild-type nucleotides, and to construct plasmids with combined
nucleotide substitutions, these converted plasmids were used next as
templates. As a result, seven variant constructs were generated from
pBFH2, and all constructs were sequenced to conﬁrm the nucleotidesubstitutions. Therewere two copies of the core promoter and precore
regions in the plasmids, and the mutations in both copies were
converted by the site-directed mutagenesis.
Cell culture and transfection
Human hepatoma HepG2 or Huh7 cells were cultured in
Dulbecco's modiﬁed Eagle medium supplemented with 10% bovine
serum at 37 °C and 5% CO2. For the assay of HBV replication, six-well
plates were seeded with 5×105 HepG2 or Huh7 cells each. On the
next day, 1.5 μg of plasmid DNA was transfected to these cells using
TransIT LT-1 Transfection Reagent (Mirus, Madison, WI), and the
culture supernatant and cells were collected 3 days later. The
transfection efﬁciency was evaluated by Great EscAPe SEAP Reporter
System 3 (Clontech, Mountain View, CA), in which 10 ng/ml of a
reporter plasmid expressing secreted alkaline phosphatase (SEAP)
was cotransfected. Experiments were performed at least in triplicate.
Detection of intracellular replicative intermediates of HBV
The core particle-associated HBV DNA in the cells was isolated as
described previously (Abdelhamed et al., 2002) with slight
modiﬁcations. Three days after transfection the cells were washed
with phosphate-buffered saline (PBS) and lysed in 400 μl of lysis
buffer (50 mM Tris–HCl, 1 mM EDTA, 1% Nonidet P-40) per well.
The lysed cells were centrifuged at 14,000 rpm for 5 min and the
supernatant was collected. To remove unprotected DNA, 10 units of
DNase I was added to 160 μl of the supernatant, followed by
incubation at 37 °C for 1 h. The reaction was stopped by EDTA, and
total DNA was extracted with a QIAamp DNA Blood Mini Kit. After
ethanol-precipitation, it was analyzed by Southern blot analysis
using a full-length HBV DNA probe labeled with PCR DIG Probe
Synthesis Kit (Roche Diagnostics). The signal of HBV DNA was
analyzed with the LAS-1000 image analyzer (Fuji Photo Film, Tokyo,
Japan) and quantiﬁed by densitometry with ImageJ 1.39u (The
National Institutes of Health, Bethesda, MD).
Quantiﬁcation of extracellular HBV DNA, HBsAg, and HBeAg
To digest the input plasmid DNA in the culture supernatant, 5 μl of
the supernatant was treated with 5 units of DNase I (TaKaRa Bio, Inc.)
at 37 °C for 1 h, and the reaction was stopped with EDTA. Then, total
DNA was extracted with a QIAamp DNA Blood Mini Kit, and 10 μl
of 200 μl DNA solution was subjected to real-time PCR using a
LightCycler system (Roche Diagnostics, Mannheim, Germany) as
described previously (Jardi et al., 2001). HBsAg and HBeAg in 50 μl of
the culture supernatant were assayed by enzyme-linked immunosor-
bent assay (ELISA), using an HBsAg ELISA kit (Hope Laboratories,
Belmont, CA) and ELISA kit for HBeAg (BioChain Institute, Inc.,
Hayward CA), respectively.
Confocal ﬂuorescence microscopy
At 48 h post-transfection, the culture slides were washed in PBS
and the cells were ﬁxed in ethanol for 10 min at room temperature
(RT). After ﬁxation, the cells were washed and incubated in
blocking solution, 10% (v/v) goat serum prepared in PBS, for
30 min at RT. The cells were incubated with a diluted (1:500) rabbit
polyclonal anti-HBcAg antibody (Dako, Glostrup, Denmark) as the
primary antibody for 1 h at RT, washed in PBS, and incubated with
Alexa Fluor 546 goat anti-rabbit IgG (Molecular Probes, Eugene, OR)
as the second antibody for 1 h at RT. At the same time, the F-actin
and nucleus were stained with Alexa Fluor 488 phalloidin
(Molecular Probes) and TO-PRO-3 iodide (Molecular Probes),
respectively. Images were captured by confocal microscopy
(Nikon, Tokyo, Japan) with EZ-C1 software.
209J. Inoue et al. / Virology 395 (2009) 202–209Immunohistochemistry
Tissue samples were obtained from three of ﬁve consecutive cases
of fulminant hepatitis B previously reported by us (Nagasaki et al.,
2008). As controls, samples from three acute hepatitis B patients and a
chronic hepatitis B patient were evaluated. For negative control, a
sample from a nonalcoholic steatohepatitis patient was also used.
Each tissue was preserved for routine pathological evaluation using
parafﬁn-embedded samples. For HBcAg immunohistochemical exam-
ination, after treatment with antigen retrieval solution (Dako) and
quenching endogenous peroxidase activity by methanol–peroxide
solution, parafﬁn-embedded liver sections (2 μm) were incubated
with a diluted (1:700) rabbit polyclonal anti-HBcAg antibody (Dako)
at 4 °C overnight. After rinsing with PBS, Histoﬁne Simple Stain MAX
PO (M) (Nichirei, Tokyo, Japan) was added for 1 h at RT. Nuclear
counterstaining was performed using hematoxylin for light micros-
copy after detecting reactions with VECTOR NovaRED (Vector
Laboratories, Inc., Burlingame, CA). These liver specimens were
observed with a digitalized light microscope BZ-8000 (Keyence,
Osaka, Japan).
Statistical analysis
Statistical analyses were performed using Mann–Whitney U test
for comparison of continuous variables between two groups. Differ-
ences were considered to be statistically signiﬁcant when Pb0.05.
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